
Background. The spread of home hemodialysis is increasing in Italy and across Europe, as noted in the document ("La diffusione dell'emodialisi domiciliare sta aumentando in Italia ed in Europa"). Its main feature enabling hospital use is its portability and independence from centralized water treatment systems, thanks to the use of sterile pre-mixed dialysate bags. This allows treatments to be delivered in environments not traditionally equipped for dialysis, such as isolation rooms on inpatient wards, emergency departments, or temporary units prior to definitive intrahospital transfer. Materials and Methods. Dialysis therapy used: The NxStage VersiHD system was employed to perform hemodialysis in three clinical scenarios: 1. Non-transportable patient with anasarca and acute kidney injury. The patient, hospitalized in the pulmonology ward and receiving oxygen therapy via tracheostomy, developed acute kidney injury with anuria requiring renal replacement therapy. The NxStage VersiHD device, already available in the dialysis unit, was transported to the patient's room. Two treatments were performed using 25 L of dialysate: the first lasting 3 hours and the second 4 hours. The system was used emergently for ultrafiltration and solute clearance until spontaneous diuresis resumed, despite a logistically challenging setting. 2. Chronic hemodialysis patient presenting to the emergency department with severe dyspnea due to fluid overload and SARS-CoV-2 infection. Because timely isolation in the dialysis unit was not feasible, urgent hemodialysis was performed using the NxStage VersiHD in a day-hospital room of our department, achieving reduction of pulmonary edema. 3. A 61-year-old woman with cirrhosis presented with splenic hemorrhage and acute renal failure. Admitted to intensive care, she underwent CVVHDF for 72 hours. She was transferred to the nephrology ward, which was not transportable due to the risk of hemorrhage. The NxStage VersiHD and the necessary equipment for dialysis scheduled for the following day were transported to the ward. Conclusions. The report aims to highlight the feasibility of using a home-designed dialysis technology safely within specific intrahospital contexts, offering an alternative strategy for dialysis support when infrastructural limitations or patient immobility prevent standard approaches. Staff training on NxStage operation, emergency procedures, and complication management is essential to minimize human error. The main challenges in training hospital nursing teams for occasional NxStage use include limited operational familiarity, management of device-specific complications, and integration of safety protocols. Operational unfamiliarity arises because, although NxStage is designed to simplify setup through preassembled cartridges and sterile dialysate bags, it differs technically from conventional dialysis systems. Lack of routine use is the primary reason for failure of NxStage implementation projects in hospital settings. To address this issue, our center adopted continuous use of NxStage in the dialysis unit for selected patients, ensuring regular machine operation. To avoid inadequate clearance with a thrice weekly schedule, 4 hour sessions were performed in patients with a distribution volume compatible with achieving a weekly Kt/V of 2.2, in accordance with international guidelines.
We report the case of a 64-year-old man referred for evaluation of progressive renal dysfunction associated with hypertriglyceridemia and non-nephrotic proteinuria. There was no evidence of plasma cell dyscrasia, chronic inflammatory disease, or other secondary causes of amyloidosis. Renal biopsy revealed amyloid deposits with predominant glomerular involvement. Congo red staining confirmed the presence of amyloid, showing characteristic apple-green birefringence under polarized light. Immunohistochemical studies were non-diagnostic. Therefore, laser microdissection followed by mass spectrometry-based proteomic analysis was performed and identified apolipoprotein C-II (ApoC-II) as the main component of the amyloid deposits. Genetic analysis subsequently demonstrated a heterozygous c.122A>C (p.Lys41Thr) variant in the APOC2 gene, confirming the diagnosis of hereditary apolipoprotein C-II-related amyloidosis (AApoC-II), a very rare form of hereditary amyloidosis with predominant renal tropism.
Background. Cardiovascular-kidney-metabolic (CKM) syndrome encompasses obesity, type 2 diabetes, cardiovascular disease, and chronic kidney disease. Insulin resistance has traditionally been considered the primary driver, with hyperinsulinemia viewed as a compensatory response. However, emerging evidence suggests that hyperinsulinemia may precede insulin resistance in specific phenotypes and contribute to early disease mechanisms. Methods. We conducted a narrative review of the role of hyperinsulinemia in CKM syndrome. Literature searches were performed in PubMed/MEDLINE, Embase, and Scopus through December 2025. We prioritised prospective cohort studies, meta-analyses, Mendelian randomisation studies, and randomised controlled trials, and synthesised evidence across cardiovascular, renal, and metabolic domains. Results. Sustained hyperinsulinemia is associated with myocardial hypertrophy and fibrosis through selective preservation of mitogenic signalling, contributing to heart failure phenotypes. In the kidney, it enhances sodium and glucose reabsorption, increases intraglomerular pressure, and promotes podocyte dysfunction, potentially accelerating CKD progression. Epidemiological evidence consistently shows associations between elevated fasting insulin levels and cardiovascular events, renal outcomes, and mortality across diverse populations, with meta-analytic estimates reporting a pooled relative risk of 1.46 (95% CI 1.16-1.84) for incident cardiovascular events. However, available data are largely observational and heterogeneous in exposure definitions and adjustment models. Conclusions. Hyperinsulinemia represents a clinically relevant and potentially modifiable component of CKM syndrome, with effects extending beyond glucose homeostasis. While causality is biologically plausible and supported by genetic and epidemiological evidence, it remains to be established through interventional studies. Recognition of hyperinsulinemia may support earlier risk stratification and mechanism-based interventions, although prospective validation is required before routine clinical implementation.
Throughout the natural history of chronic kidney disease (CKD), most patients experience fatal or non-fatal cardiovascular events. In this review, we address the role of low-density lipoprotein cholesterol (LDL-C) in the excess cardiovascular risk associated with CKD and examine the impact of both traditional and novel LDL-C-lowering therapies across the entire spectrum of CKD. Current guidelines for the prevention of atherosclerotic cardiovascular disease (ASCVD), developed by European and US cardiology societies, recommend assessment of overall cardiovascular risk to tailor the intensity of preventive strategies to the individual patient's risk profile: the higher the cardiovascular risk, the more intensive the intervention should be. Novel therapies have demonstrated efficacy in achieving lower LDL-C targets, which are often unattainable with conventional treatment. The identification of vulnerable coronary plaques, rather than the mere presence of vascular lumen narrowing, represents a promising imaging target for guiding intensified preventive strategies in high-risk populations, including patients with CKD. In CKD, cardiovascular risk progressively increases as kidney function declines. Despite clear recommendations from both nephrology and non-nephrology guidelines, initiation, maintenance, and intensification of lipid-lowering treatment, as well as achievement of LDL-C targets, remain suboptimal in the CKD population. As novel lipid-lowering therapies provide additional therapeutic options for patients with CKD, there is now a compelling need to increase awareness of cardiovascular risk and integrate lipid management into the broader, longitudinal care of patients with CKD across all stages of the disease.
Ultrasound is nowadays widely used in nephrological practice as a first-line clinical tool. Despite this widespread adoption of the technique, the medico-legal aspects of ultrasound reporting have so far received limited attention, even though the report represents the formal completion of the medical act and the only document endowed with probative value. In the legal context, in fact, the ultrasound examination can be assessed exclusively through what is documented in the report, regardless of the technical quality of the examination itself. The present paper analyzes the main medico-legal aspects of ultrasound reporting, with particular reference to the activity of the nephrologist, focusing on the essential requirements of the report, the most common critical issues with medico-legal relevance, and the implications in terms of professional liability. The role of declaring the limitations of the examination and of structured reporting as possible tools for clinical risk management and professional protection will also be examined.